They recommend the use of the pill in adults with a high risk of progress of Covid, if the infection is mild to moderate.
Approval of the oral pill, Paxovid , by the US Food and Drug AdministrationUSA (FDA), has been officially announced. Previously cleared by the FDA for emergency use only, this drug is the first oral antiviral drug approved to treat COVID-19 in adults.
According to the FDA statement, the oral antiviral also showed evidence of benefit in patients who already had immunity against the virus that causes the infection.COVID-19. Its use is recommended in adults with a high risk of disease progression, if the infection is mild to moderate.
In the research conducted, the risk of COVID-19-related hospitalization or death at 28-day follow-up was 0.2% for the 490 people who received Paxovid , compared to 1.7 for the 479 who received a placebo. %.
The director of the FDA’s Center for Drug Evaluation and Research , Patrizia Cavazzoni, said in the briefing note that the approval “demonstrates that it has met the agency’s rigorous safety and efficacy standards.”
This drug is the fourth to be approved by the FDA to treat COVID-19 and is an important treatment option for people withhigh risk of developing severe COVID-19, especially for those who already have prior immunity.
